AbbVie

ABBV

Market cap $384B

Ten years ago, AbbVie (NYSE:ABBV | ABBV Price Prediction) was a one-drug story.

ABBV wins EU approval for Aquipta for acute migraine treatment in adults, adding a second approved indication in migraine.

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The drug industry has been working on how to shuttle drugs through the blood-brain barrier, and the results will become apparent this year.

NORTH CHICAGO, Ill., June 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026.

AbbVie Inc. (ABBV) Presents at EU Clinical Trial Regulation: Latest Developments and Upcoming Opportunities Transcript

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?

Addition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase 3 AMPLIFY trial, Phase 3 GLOW trial and Phase 2 CAPTIVATE trial Fixed-duration VENCLYXTO-based combination regimens provide patients with additional CLL treatment options that may offer the potential for treatment-free intervals NORTH CHICAGO, Ill., May 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has authorized an expanded label for VENCLYXTO® (venetoclax) to include use in combination with acalabrutinib (with or without obinutuzumab) and use in combination with ibrutinib for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL).

ABBV's Decnupaz wins FDA approval for BPDCN, adding its first blood cancer ADC and a new option for an ultra-rare aggressive malignancy.

- DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient setting - DECNUPAZ marks AbbVie's first ADC approved for blood cancer NORTH CHICAGO, Ill., May 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZTM (pivekimab sunirine-pvzy) for the treatment of adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy with limited treatment options.